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In monoaminergic ells, the neurotransmitter is accumulated into secretory or synaptic vesicles by a tetrabenazine- and reserpine-sensitive 
transporter, catalyzing an H+/monoamine antiport. The major vesicular monoamine transporter from bovine chromaffin cells was cloned, using 
sequences common to adrenal medulla and brain rat vesicular monoamine transporters. Its identity was confirmed by peptide sequences, determined 
from the purified protein. Surprisingly, the bovine adrenal medulla sequence, bVMAT,, is more related to the transporter from human and rat 
brain than to that from rat adrenal medulla. PCR amplifi~tion showed that bVMAT, is expressed in both adrenal medulla and brain, in contrast 
with the situation reported in rats, where distinct genes appear to be expressed in brain (SVAT or MAT, now renamed rVMAT& and in the adrenal 
medulla (CGAT, now renamed rVMA’I’,). In bovine ~hromaffin cells, long-term depolarization by KCI resulted in an increase in the level of 
bVMAT, mRNA, in agreement with the previously observed increase in the transporter binding sites, suggesting that a coupiing between 
stimulation, secretion and synthesis changes the composition of the secretory granule membrane. 
Chromaffin granule; Neurotransmitter transporter; Stimulation-secretion coupling; Synaptic vesicle 
1. INTRODUCTION 
Vesicular transporters accumulate neurotransmitters 
into synaptic vesicles, prior to their release. The most 
extensively studied transporter of this type is the vesicu- 
lar monoamine transporter (VMAT) of chromaffin 
granules, because of the availability of bovine chro- 
maffin granules. Monoamine uptake through the vesic- 
ular transporter is driven by the H+-electrochemical 
gradient generated by a V-type ATPase located on the 
same membrane (for review see [ 11). The transporter has 
been characterized pharmacologically with the specific 
inhibitors reserpine, tetrabenazine, and various deriva- 
tives. Ketanserin, an antagonist of 5-HTz receptors, also 
binds to the same site as tetra~nazine [2]. These ligands 
have been used to purify the transporter in an active 
f3,4] or inactive form [5]. In addition, a pharmacological 
analysis of bovine chromaffin cells in culture suggested 
that the expression of the vesicular monoamine trans- 
porter is up-regulated under depolarizing conditions [6]. 
In rat, vesicular monoamine transporters have been 
cloned by expression in mammalian cells by two differ- 
ent laboratories [7,8]. Although the existence of multiple 
VMAT genes was not anticipated since pharmacologi- 
cal and biochemical studies had not revealed any func- 
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tional or structural heterogeneity among transporters 
from different tissues [9], Liu et al. [7] reported that rats 
possess two related genes. Our gene is expressed in adre- 
nal medulla and in PC12 cells (CGAn, while the other 
is expressed in brain @VAT). The transporters are not, 
however, specific for peripheral vs. central nervous sys- 
tem, since Erickson et al. [S] reported that MAT (iden- 
tical to SVAT), which was derived from the rat baso- 
philic leukemia cell line RBL 2H3, is expressed in the 
brain and in the stomach. It has therefore been agreed 
at a recent international meeting to rename these trans- 
porters VMAT, and VMAT,, respectively (‘Molecular 
aspects of neuronal transporters’, Strasbourg, Septem- 
ber 26-30, 1993). 
In the present co~unication, we describe the clon- 
ing of the monoamine transporter from bovine adrenal 
medulla, which has been extensively analyzed biochem- 
ically and pharmacologically, and we show that the 
corresponding mRNA is upregulated in depolarised 
chromaffin cells, in culture. 
2. MATERIALS AND METHODS 
2.1. RNA purification. cDNA library construction andlibrary screening 
Total RNA was extracted from bovine chromaffin cells cultured for 
2 days in the presence of 60 mM KCI, which overexpress the vesicular 
monoamine transporter 161. using RNazoI (Bioprobe, Montreuil, 
France) according to [IO]. Poiy(A)’ fraction was purified with oligo 
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dT Dynabeads (Biosys, Compiegne, France). cDNA synthesis and 
cloning were achieved using /1ZAP II vector with the ZAP-cDNA 
synthesis kit from Stratagene (La Jolla, USA). This cDNA library 
(4 x lo5 clones) was screened with the oligonucleotide TR, deduced 
from a region highly conserved between the nucleotidic sequences of 
rVMAT, and rVMAT, (corresponding to amino acids 313-325 in 
rVMAT, and 317-329 in rVMAT,, located between the 7th and 8th 
transmembrane s gments); TR, was labelled with “P using T, polynu- 
cleotide kinase and [Y-‘~P]ATP (6,000 Ci/mmol) (NEN, Du Pont de 
Nemours, France). Hybridizations were performed in 7% SDS, 0.25 
M Na phosphate, 0.25 M NaCl at 53°C overnight. Filters were washed 
in 1% SDS, 0.2 M Na phosphate, at 53°C. We obtained about 60 
clones, all corresponding to the same incomplete cDNA. 
2.2. Obtention of a complete VMAT, clone by the RACE 5’ procedure 
We followed the procedure described by Frohman [1 l] and modified 
by Delort et al. [12]. Briefly, oneyg of total RNA from K’ depolarized 
chromaffin cells was submitted to reverse transcription using the TA, 
oligonucleotide as a primer in Taq buffer (50 mM KCI, 2.5 mM 
MgCl,, 0.1 mg/ml BSA, 20 mM Tris-HCl, pH 8.4). Single-stranded 
cDNA was purified using glass MAX (Gibco BRL). The purified 
cDNA (l/5 of the preparation) was used directly for dA-tailing with 
10 units of terminal deoxynucleotide transferase in 20 ~1 of twice 
diluted Taq buffer, containing 0.2 mM dATP (10 min incubation at 
37°C). The tailed cDNA (5 ~1) was directly used for the first PCR 
amplification in 50 ~1, containing primers TA, and R, (10 pmol each), 
dT adaptor (2 pmol), 2.5 units Taq DNA polymerase (Bioprobe Sys- 
tems), 200 PM dNTP, 150 fig/ml BSA, 16 mM (NH&SO,, 2.5 mM 
MgCl,, 20 mM Tris-HCI, pH 8.55. Complementary strands were an- 
nealed for 2 min at 45°C and extended for 40 min at 72°C. Thirty 
cycles (45 s at 94°C 1 min at 50°C 3 min at 72°C) were carried out 
in a Techne PHC3 thermocycler. A second round of amplification was 
carried out for 30 cycles, adding oligonucleotides R, and TA, or TA, 
to 1150 of the products of the first amplification. The products were 
separated by electrophoresis n agarose gel and purified. The largest 
molecules were cloned in Bluescript vector and sequenced. A complete 
clone was constructed in the CDM8 expression vector by PCR fusion 
of RACE 5’ products. 
cDNA clones, derived from incomplete clones or obtained by the 
RACE 5’ procedure, were sequenced by the dideoxy method with 
Sequenase (USB). Reconstruction of the full sequence in CDM8 vec- 
tor was achieved by primer walking. Compilation of sequence data 
and restriction maps was done with the programme written by Bellon 
[13]. Alignment and screening of protein sequences were done using 
the GCG package (University of Wisconsin, USA). 
2.3. RT-PCR and competitive PCR 
Reverse transcription was performed with total RNA (I pg) in 20 
~1 of Taq buffer containing 7 mM MgCl,, 200 PM dNTP, 1 pmol of 
TA, and 10 units of AMV reverse transcriptase (Promega). The mix- 
ture was incubated for 40 min at 42°C and the enzyme was inactivated 
by incubation at 70°C for 10 min. The RT product was directly 
transferred to a tube containing 10 units/ml of Taq polymerase and 
dNTP in Taq buffer without MgCl, (80 ~1 final volume). 
For competitive PCR, the competitor was a 540 bp fragment, ampli- 
fied with oligonucleotides TA, and TA, from the rat SVAT (rVMAT,) 
clone, a gift from Dr. R.H. Edwards. The rat (competitor) and bovine 
(target) cDNA were discriminated by restriction with BarnHI, which 
produced fragments of 320 and 220 nucleotides for rVMAT, and 120 
and 420 nucleotides for bVMAT,. Stock solutions of the computer 
were prepared by serial dilutions from 0.25. IO-” to 2.5. IO-l2 mol. 
The reverse transcriptase product was diluted in 450 ~1 of Taq buffer, 
0.2 mM dNTP (50 &i/ml of “P dCTP), 10 pmol of each primer, 10 
units of Taq polymerase per ml. An aliquot (45 yl) was transferred to 
each competition tube containing the diluted competitor (5 ~1) and 
then overlaid with mineral oil. After 45 cycles (1 min at 94°C 1 min 
at 53”C, 1 min at 72°C) 10 ~1 of the products were diluted in 20 ~1 
of BamHI buffer and incubated for 1 h. The mixture was analyzed by 
electrophoresis n 5% polyacrylamide gels; the gels were fixed, dried 
and the radioactivity quantified with a Phosphorimager (Molecular 
Dynamics). 
2.4. Protein pur$cation and sequence determination 
The vesicular monoamine transporter was purified from bovine 
chromaffin granules by the procedure of Isambert et al. [5] and by a 
technique to be described (Gasnier, B., Sag& C. and Henry, J.P., in 
preparation). Peptides generated by CNBr cleavage were separated by 
reverse phase HPLC on an Aquapore RP-8 column, 100 x 2.1 mm 
(Brownlee). The peptides were eluted in trifluoroacetic acid (TFA) 
0.1% (v/v) with a gradient of 70% acetonitrile (v/v) containing 0.08% 
TFA, at a flow rate of 200pVmin. Amino acid sequence determination 
was performed on an Applied Biosystems equencer (model 477A) 
equipped with an on-line phenylthiohydantoin analyser (model 120A). 
2.5. Oligonucleotides 
We used the following oligonucleotides (all in the 5’ to 3’ orienta- 
tion): 
TR,: GAGCCCACGCTGCCCATCTGGATGATG(C/G)AGACCA- 
TGTG 
TA,: ATCCCATACAAAACGCAACATCG 
TA,: CCCAGTGAAGACAAAGACCTCCT 
TA,: ACAGATGACGAGGAGAGGGG 
TA,: CTCCAAAGTTGGGAGCTATGAGT 
TA,: CGGAATTCGACTTCCCCACAAACTCGTA 
TA,: AGGTGGTCGGTGCTGTT 
TA,: CCAGACCACCCCGAGCC 
dT adaptor: AAGGATCCGTCGACATCGATAATACGACTCA- 
CTATAGGGA (T),, 
Ro: GAAGGATCCGTCGACATCG 
R,: TCGACATCGATAATACGACTCAC 
3. RESULTS 
3.1. cDNA cloning and sequence analysis of a b VMAT 
cDNA clone 
We purified the monoamine transporter from bovine 
chromaffin granules to homogeneity and determined 
Table I 
Peptidic sequences derived from purified chromaffin granule monoamine transporter analysis 
Peptide Determined sequence Position in the 
bVMAT, sequence” 
N-terminal ALSxLALLxxLQ 2 
CNBr peptide E, LLTVVVPIIPSYLYxIExxK 36 
CNBr peptide E,, xAFSxSYAFLLIARSLQG1 179 
CNBr peptide Ez3 xVLVGPPFGxVLYE 234 
a The numbers indicate the position of the N-terminal residue of the peptide in the bVMAT, sequence, as shown in Fig. 1. Non identified residues 
are indicated by x. 
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peptidic sequences from the N-terminus and from 
CNBr fragments (Table I). Because these sequences 
contained numerous uncertainties and did not allow us 
to prepare satisfactory oligonucleotide probes for clon- 
ing the transporter, we used a strategy based on the 
homology between the two rat vesicular amine trans- 
porters, rVMAT, and rVMAT, [7]. We reconstructed a 
complete cDNA clone by screening and RACE 5’. 
The nucleotide and deduced protein sequences are 
given in Fig. 1. The predicted protein clearly corre- 
sponds to the monoamine transporter which had been 
purified from bovine chromaffin granules and charac- 
-93 cecaagcttctaqagatccctcgacctegbcatccattgt~=~=~===~= 
-43 tagtggatccaggccagaccaccccgagccqagcccagga~~= ATG GCC CTG AGC GAG CTG GCG CTG CTC 
1 M A L s E i A L L 
28 CGC CGG CTT CAG GAG AGC CGG CAC TCG CGG AAG CTC ATC CTG TTC ATC GTG TTC CTC GCG 
10 R R L Q E S R H S R K L I L F I V F L A 
;i Cy CT C;G GE, 2” A? Cr CTC ACG GTT GF GTC CCC ATC ATC CCG AGT TAC TTG TAC 
L T V v P I I P s Y L Y 
148 AGC ATT GAG CAT GAG AAA CAT GCT CTA GAA ATC CAG ACC ACC AAG CCC GGG CTC ACA GCC 
50 S I E H E K D A L E I Q T T K I? G L T A 
TCC GCC CCC GGG AGC TTC CAG AAC ATC TTC TCC TAT TAT GAC AAC TCC ACC ATG GTC ACC 
SAPGSFQNIFSYYDNSTMVT 
268 GGG AAC AGC ACC GAC CAC CTT CAG GGG GCG CTG GTG CAC GAG GCC ACC ACG CAG CAC ATG 
90 G N S T D H L Q G A L V Ii E A T T Q H M 
328 GCC ACT AAC TCG TCC TCG GCC TCT TCC GAC TGT CCC AGT GAA GAC AAA GAC CTC CTG AAT 
110 A T N S S S A S S D C P S E D X D L L N 
388 GAG AAT GTG CAG GTC GGG CTG CTG TTT GCC TCG AAA GCC ACT GTC CAG CTC CTC ACC AAC 
130 E N V Q V G L L F A S K A T V Q L L T N 
448 CCG TTC ATA GGA CTG TTG ACC AAC AGA ATT GGC TAC CCA ATT CCC ATG TTT ACG GGA TTC 
150 PFIGLLTNRIGYPIPHFTGF 
508 TGC ATC ATG TTT ATC TCA ACA GTT ATG TTC GCC TTC TCC CGC AGC TAC GCC TTC CTG CTG 
170 CIMFISTVMFAFSRSYAFLL 
568 ATC GCC AGG TCC CTG CAG GGC ATC GGT TCC TCC TGC TCA TCT GTA GCT GGC ATG GGC ATG 
190 I A R S L Q G I G S S C S S V A G M G M 
628 CTG GCC AGC GTG TAT ACA GAT GAC GAG GAG AGG GGC AAC GCC ATG GGG ATC GCC CTG GA 
210 LASVYTDDEERGNAMGIALG 
68% GGC CTG GCC ATG GGG GTC CTA GTG GGC CCC CCC TTT GGG AGT GTG CTG TAC GAG TTT GTG 
230 G L A M G V L V G P P F G S V L Y E F V 
748 GGG AAG ACA GCT CCG TTC CTG GTC TTG GCT GCC CTG GTG CTC TTG GAT GGA GCC ATT CAG 
250 G K T A P F L V L A A L V L L D G A I Q 
808 CTC TTT GTG CTC CAG CCG TCC CGG GTA CAG CCA GAG AGC CAG AAG GGG ACG CCG CTC ACC 
270 LFVLQPSRVQPESQKGTPLT 
86% ACC CTG CTG AGG GAC CCA TAC ATC CTC ATC GCT GCA GGG TCC ATC TGC TTC GCA AAC ATG 
290 TLLRDPYILIAAGSICFANM 
92% GGG ATT GCC ATG CTG GAG CCA GCC CTG CCC ATC TGG ATG ATG GAG ACC ATG TGT TCC CRC 
310 GIAMLEPALPIWMt4ETMCSH 
989 AAG TGG CAG CTG GGC GTG GCT TTC TTG CCA GCT AGC GTC TCT TAT CTC ATT GGA ACC RAT 
330 K W Q L G V A F L P A S V 5 Y L I G T N 
1048 GTT TTT GGG ATC CTC GCA CAC AAA ATG GGG AGA TGG CTT TGT GCT CTT CTA GGA ATG ATA 
350 VFGILAHKMGRWLCALLGMI 
1108 ATT GTC GGA ATG AGC ATT TTA TGT ATT CCT CTT GCA AAA AAC ATC TAC GGA CTC ATA GCT 
370 I V G M S I L C I P L A K N I Y G L I A 
1168 CCC AAC TTT GGA GTT GGT TTT GCA ATT GGC ATG GTG GAT TCA TCA ATG ATG CCC ATC ATG 
390 P N F G V G F A I G M V D 5 S M M P I M 
1228 GGC TAT CTG GTC GAC CTG CGG CRC GTG TCG GTC TAT GGG AGC GTG TAC GCC ATT GCC GAT 
410 G Y L V D L R H V S V Y G S V Y A I A D 
1288 GTT GCG TTT TGT ATG GGA TAT GCC ATA GGT CCT TCT GCT GGT GGG GCT ATC GCA AAG GCA 
430 V A F C M G Y A I G P S A G G A I A K A 
134% ATT GGA TTT CCA TGG CTC ATG ACA ATT ATT GGA ATA ATT GAT ATT TCT TTT TTT GCT CCT 
450 IGFPWLMTIIGIIDISFFAP 
1408 CTC TGC TTT TTT CTT TCG AAG TCA CCT GCC AAG GAA GAA AAA ATG GCT ATC CTC ATG GAT 
470 LCFFLSKSPAKEEKMAILMD 
146% CAC AAC TGC CCC ATT AAA ACA AAA ATG TAC ACG CAG AAC AGC AGC CAG TCG CAT CCG ATA 
490 H N C P I K T K M Y T Q N S S Q S H P I 
152% GGT GAG GAT GAA GAA TCT GAA AGT GAC TGA gacccgcaaaagt~ctccabgtacctaattgtataaaag 
510 G E D E E S E S D / 
1597 tytttccagtgaaatgactcatccagaactgtcttagtcataccactcatccct~gtgaaagtcatacaaccaaaggtt 
1676 ccttcttttccaggttaatcgatt 
Fig. 1. Complete coding sequence and deduced primary sequence of bVMAT,. The nucleotide sequence corresponds to the reconstructed clone 
obtained from partial cRNA clones, extending up to nucleotide 337, and completed by RACE 5’. The coding sequence is complete, since it contains 
the N-terminal peptide sequence, and was able to generate active transport of catecholamines in transfected cells (manuscript in preparation). 
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terized biochemically, since it contains the N-terminal similar to rVMAT, and hVMAT, (88% and 89% iden- 
26 amino acids identified by Stern-Bach et al. [14], as tiy, respectively), previously identified in rat and human 
well as the internal peptide sequences determined by brain, than to rVMAT, (63% identity), obtained from 
outselves (Table I). the rat adrenal medulla. 
In Fig. 2, this sequence, bVMAT,, is compared with 
the published sequences rVMAT,, from rat brain [7,8], 
hVMAT,, from human brain [15], and rVMAT,, from 
rat adrenal medulla [7]. The sequence of bVMAT, indi- 
cates a general organization similar to that of the other 
VMAT genes, with 12 putative transmembrane seg- 
ments, both N- and C-terminal parts of the protein 
being in the cytoplasm, and a large luminal loop be- 
tween the first and the second transmembrane seg- 
ments. Alignment and comparison of the VMAT amino 
acid sequences indicate that bVMAT, is more closely 
The difference between the VMAT, and VMAT, se- 
quences is particularly striking in the N- and C-terminal 
parts of the protein and for the large intravesicular loop 
(P42 to G135), which represents the most divergent do- 
main between the four sequences: the loop of bVMAT, 
is 59% identical to that of rVMAT,, 72% to hVMAT,, 
and 22% to rVMAT,. Moreover, this loop contains an 
hypervariable region, extending from T86 to S115. The 
sequence of bVMAT, contains three putative N-glyco- 
sylation sites in the large intravesicular loop, instead of 
four sites for hVMAT, and rVMAT,. In the putative 
bVMT-1 
rVMT-1 
hVMT-1 
rVMT-2 
bVMT-1 
rVMT-1 
hVMT-1 
rVMT-2 
1 
-MALSELALLRRLQESRHSRKL 
1 
mlqvvlg pq 1 k g q 
67 134 
LTASAPGSFQNIFSYYDRST-MVTG~STDHLQGALVHEATTQHMAT~SSSASSDCPSEDKDLL-NENVQV 
vv tse --- iit? vli 8a gt p gqs k stqhtvafittvp r - 
h isd s n - Aa rd ---tl qta v Ra avp 
qq ltspa st ff tit tt eehvpfrv---twtiig ipppv ea vpknnclqgief ee ri 
rVMT-1 
bVMT-1 
rVMT-1 
hVMT-1 
rVMT-2 
bVMT-1 
rVMT-1 
hVMT-1 
rVMT-2 
405 518 
AILMDHNCPIKTKMYT-QnSSQSHPIGEDEESESD-- 
r -nvy d __ 
- ni y -- 
-sqe ta q f kptkaf 1 nsddp sge 
Fig. 2. Comparison of vesicular monoamine transporter sequences. The full sequence of bVMAT,, the vesicular monoamine transporter from bovine 
chromaffin granules deduced from our cloned cDNA, is shown in capital letters. For the other sequences, only divergent residues are shown, in 
lower case letters; rVMAT, and rVMAT, were deduced from rat cDNA sequences ([7] Genbank accession numbers M97381 and M97380) and 
hVMAT, from a human cDNA sequence ([15] Genbank accession number LO91 18). Putative N-glycosylation sites are indicated in bold type. 
Putative transmembrane domains are indicated by boxes. Numbers refer to the bovine sequence (bVMAT,). Gaps introduced for alignment are 
indicated by dashes. Potential N-glycosylation sites are indicated by fi for conserved sites and ti for other sites. 
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transmembrane segments, the positions of the charged 
residues are conserved among bovine, human and rat 
VMAT2 (five acidic residues, D33, D265, D402, D429 
and D463, and one basic residue, K141), whereas the 
rVMAT, sequence does not contain the last aspartic 
acid. Finally, three protein kinase C phosphorylation 
sites are conserved between the three VMAT, sequences 
(S18, T156 and S282), whereas only two are present in 
rVMAT,. 
3.2. Regulation of the expression of bVMAT, 
The presence of mRNA encoding bVMAT, in the 
brain, as well as in adrenal medulla, was demonstrated 
by PCR amplification of reverse transcriptase products, 
using TA, and TA4 oligonucleotides derived from 
bVMAT, (Fig. 3). 
In Northern blots, we observed a 4 kb transcript in 
bovine adrenal gland and in cultured chromaffin cells 
(Fig. 4). This mRNA was overexpressed in cells cul- 
tured for 2 days in the presence of 60 mM KCl, in 
agreement with the fact that the number of [3H]TBZOH 
binding sites was previously found to increase after long 
term depolarization [6]. Using competitive RT PCR 
[16], we found that the level of bVMAT, mRNA was 
increased about 3-fold after 4 hours and rapidly reached 
a plateau, in these conditions (Fig. 5). 
RT- RT+ 
0 ABMAB 
Fig. 3. RT-PCR analysis of bVMAT, expression in bovine adrenal 
medulla and brainstem. RNA (4 pg) from adrenal medulla (A) or 
brainstem (B) were incubated with primer TA, in the presence (RT+) 
or absence (RT-) of reverse transcriptase. A control incubation was 
performed without RNA (0). Ahquots (l/2 of the incubation) were 
subjected to PCR amplification (35 cycles) with ohgonucleotides TA, 
and TA, and analyzed by electrophoresis n agarose. M indicates the 
size markers (one kb ladder); the arrow indicates the amplification 
product (946 bp). 
C D 
- 4.40 
- 2.37 
4. DISCUSSION 
We obtained a cDNA clone encoding the vesicular 
monoamine transporter from bovine chromaffin gran- 
ules, bVMAT,, since the protein sequence derived from 
bVMAT, clone contains the peptides determined by 
sequencing the bovine protein obtained by ourselves as 
well as by another group [14]. Surprisingly, bVMAT, is 
closely related to hVMAT, [9] obtained from a brain 
library, and to rVMAT, [7,8] also obtained from brain 
and found not to be expressed in rat adrenal medulla, 
but it is more distant from rVMAT,, which is derived 
from PC12 cells. Comparison of the four sequences 
clearly shows the existence of two transporter types, 
now named VMAT, and VMAT,, thus avoiding any 
reference to any tissue specificity. 
Our results clearly show that the two transporters, 
VMATz and VMAT,, are not restricted to either the 
central or the peripheral nervous systems. In bovine, the 
bVMAT, gene is expressed in both brain and adrenal 
medulla. In addition, we found that another gene, pos- 
sibly related to rVMAT,, is also expressed in the bovine 
adrenal medulla (data not shown). Thus, at least two 
genes encode vesicular monoamine transporters, but 
their precise relationships remain to be understood. 
Analysis of [3H]TBZOH binding showed that the 
level of the vesicular transporter is increased in chroni- 
cally depolarized chromaffin cells [6]. We now show 
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4* - m.” 
DEPOLARIZED 
5 10 15 20 40 80 250 
-****Lw 
‘--auFi91pyl 
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Tl 
Cl 
c2 
T2 
2.5 3 3.5 4 4.5 
log10 (competitor) 
Fig. 5. Competitive reverse transcriptase-polymerase chain reaction 
(RT-PCR) analysis of bVMAT, induction in Kf-depolarized chro- 
maffin cells. cDNA originating from bovine chromaffin cells cultured 
in standard or in K’-containing medium were amplified together with 
serial dilutions of a fragment of rVMAT,, acting as a competitor. The 
single-stranded cDNA obtained by reverse transcription of chro- 
maffin cell RNA was mixed with various concentrations of rVMAT,, 
and subjected to amplification. The amplification products, obtained 
with the same primers, were of equal lengths but could be distin- 
guished by the size of fragments obtained after cleavage with BumHI. 
(A) Scanning of the dried gel: the target, bVMAT,, and the competi- 
tor, rVMAT,, produced bands T,, T, and bands C,, C,, respectively. 
The number of competitor copies (x 100) used in the amplification, is 
indicated for each lane. (B) Logarithmic plot of the data: control cells 
(0); cells which had been depolarized for two days, in the presence of 
60 mM KC1 (0). 
that the level of mRNA encoding bVMAT, is also in- 
creased under these conditions. The increase in 
bVMAT, mRNA, as measured by competitive PCR, is 
similar to that reported for tyrosine hydroxylase [17] or 
components of the granule matrix such as proenkephal- 
ine [IQ which are regulated at the transcriptional level. 
This is the first time that such a regulatory process is 
described for a neurotransmitter transporter. If the ve- 
sicular uptake is rate-limiting under conditions of pro- 
longed secretion, as discussed in detail elsewhere 
(Desnos, C., Laran, M.P. and Henry, J.P., manuscript 
in preparation), increased expression of the vesicular 
monoamine transporter would serve an adaptive pur- 
pose, and could be important from a clinical point of 
view. It has been proposed that neurodegenerative dis- 
eases, such as Parkinson’s disease, are accompanied by 
a prolonged overstimulation of the remaining neurons. 
In a clinically silent phase, masking the evolution of the 
degenerative process, these neurons would thus adapt 
by increasing the synthesis of limiting components, per- 
haps including the vesicular transporter. 
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